Ridgeback Capital, founded by Wayne Holman, chosen for its unique business acumen and network connections to be part of series B funding for Crisp – 2.2.2022
Global News Wire
Ridgeback Capital invests in Freenome, a Multiomics platform for early cancer detection for early cancer detection – 12.7.2021
PR News Wire
Quell Theapeutics Raises $156M in series B, led by Ridgeback Capital – 11.29.2021
Ridgeback Capital, founded by Wayne Holman, joins investment in Arbor Biotechnologies Series B Financing to Advance Next-Generation Precision Editing Therapeutics – 11.9.2021
Globe Newswire
Wayne Holman’s Ridgeback Capital invests in Series A for stem cell transplant company Garuda Therapeutics - 9.23.2021
BusinessWire
Ridgeback Capital leads Series A round for Reverie Labs, a pharmaceutical company using machine learning to develop small molecule kinase inhibitors – 2.3.2021
Ridgeback Capital, founded by Wayne Holman, to participate in Aro Biotherapeutics $88 Million Financing of Advance Development of Centyrin-Targeted Genetic Medicines – 1.5.2021
Business Wire
Wayne Holman, Wendy Holman of Ridgeback Biotherapeutics developed Molnupiravir with Merck, which goes through clinical trials to treat symptoms of Covid-19. 12.23.2021
Science.org
Wayne Holman and Wendy Holman, founder of Ridgeback Biotherapeutics created a pill to transform Covid-19 treatment by significantly lessening symptoms. 12.20.2021
Wall Street Journal
Ridgeback Biotherapeutics founders Wendy Holman and Wayne Holman on changing the course of the pandemic. 6.29. 2020
FT.com
